Viit Health is entering commercialization — and as we begin scaling, we’re giving the WeFunder community access to a private Pre-Series A opportunity with preferred terms and exciting special perks!

Our mission is bold: reshape the future of healthcare by making prevention simple, personalized, and accessible — helping extend 1 million lives by 10 healthy years over the next decade.

Viit has built a non-invasive health monitoring platform that combines a pocket-sized optical device, AI-powered analytics, and personalized insights. Using light instead of needles or consumables, Viit measures blood glucose, blood pressure, oxygen saturation, heart rate, and other key biomarkers in under 30 seconds.

With fast, painless monitoring and real-time personalized insights, Viit is designed to help detect early signs of health risk before disease progresses — empowering people, clinicians, and organizations to act sooner and help people stay healthier for longer.

Today’s healthcare system is not truly built around health — it is built around disease.

Non-communicable diseases (NCDs) like hypertension, heart disease, diabetes, and other metabolic disorders account for over 70% of deaths globally — claiming more than 40 million lives each year. Often symptomless in early stages, conditions like high blood pressure — affecting more than 1.2 billion people worldwide — or glucose-related dysfunction — estimated to impact half the world’s population — progress silently until disease becomes unavoidable.

These threats, driven by sedentary lifestyles, poor nutrition, chronic stress, and inequitable access to healthcare, can lead to heart attacks, strokes, kidney failure, and neurodegenerative conditions. The crisis isn’t just medical — it’s a failure of early detection and accessible prevention.

Monitoring vital health markers like blood glucose, blood pressure, and oxygen saturation remains a slow, fragmented, and costly process—especially for those at risk of chronic disease. Individuals often need multiple separate devices, each requiring setup, calibration, and manual interpretation.

Blood glucose tracking, for example, still relies on painful finger pricks or expensive continuous monitors that involve frequent sensor insertions—costing users up to $3,600 annually. For many, especially those already managing complications like neuropathy, these tools are not just uncomfortable—they are unsustainable. At the clinic level, conducting a full assessment of basic vitals can take up to 17 minutes and cost nearly $15 per patient. These inefficiencies not only drive up costs but discourage consistent monitoring, delay diagnosis, and ultimately make prevention inaccessible for millions.

Viit Health uses light and AI to measure key health biomarkers in a fast, painless, and non-invasive way. In 30 seconds, our device can measure blood glucose, blood pressure, oxygen saturation, heart rate, and more — without finger pricks, consumables, or multiple devices.

Traditional clinical measurements can take up to 17 minutes and cost more than $15 per patient. Viit can complete a measurement in seconds for as little as $0.20, reducing time by up to 97% and cost by up to 98%.

Our proprietary, patent-pending technology combines multiple optical and sensing methods into a compact device, connected to AI-powered software for signal analysis, longitudinal tracking, and personalized insights. This integrated approach allows us to capture stronger physiological signals and deliver more accurate, actionable health insights than single-sensor or algorithm-first solutions.

Instead of overwhelming users with too much data, Viit focuses on the insights that matter most. By combining high-quality signals, efficient hardware, and AI, we aim to make real-time health monitoring more accessible for individuals, clinics, companies, and public health programs.

Over seven years of R&D and multiple generations of device innovation, Viit Health has refined its proprietary technology through extensive calibration, signal optimization, and clinical validation. Since 2018, we’ve collaborated with leading healthcare institutions in the U.S. and Mexico, deploying 5 clinical studies and validating our technology in over 3,900 individuals to date.

With current results showing 3.4 BPM Mean Absolute Error (MAE) for heart rate, 0.9% MAE for SpO₂, 4.1 - 7.2 mmHg MAE for blood pressure, and 6.4 - 15.7 mg/dL MAE for blood glucose levels, we have closed the gap between non-invasive wellness monitoring and clinical-grade performance. Over the next 18 months, we will complete FDA regulatory approval as a Clinical Decision Support System (CDSS) aimed toward cardiometabolic risk observation.

* Preliminary results in controlled clinical settings / 1) Mean Absolute Error / 2) Calculated against gold-standard references / 3) Latest preliminary results obtained through cross-sectional and OGTT clinical studies for a wide glycemic range (49 - 489 mg/dL).

Our active clinical studies are in two of the largest hospitals in Mexico: Hospital General de México and Hospital Juárez de México.

Prevention is the only sustainable way to reduce the burden of chronic disease. Yet today, large-scale screening remains slow, expensive, and fragmented, making it difficult for organizations to identify risk early and act before health problems become more serious.

Viit Health is built for population-level clinical monitoring. Our Hardware & Software-as-a-Service model, starting at $550 per month, combines non-invasive measurement devices, monitoring software, healthy habits coaching, and clinical oversight into one scalable service. This enables employers, clinics, hospitals, public health programs, and institutional partners to monitor key cardiometabolic biomarkers across large groups over time.

Rather than selling hardware alone, Viit delivers a complete monitoring platform that helps organizations track health trends, identify emerging risks, and support earlier preventive action. In parallel, we will also license our technology to strategic distribution partners, allowing Viit to scale through established commercial channels while expanding access to preventive health monitoring.

By reducing the time, cost, and complexity of traditional screening, Viit makes prevention practical at scale.

Viit Health is directly addressing a $780B+ global market opportunity driven by the shift toward personalized, preventive healthcare. With an initial focus on North and Latin America, we see a $338B total addressable market, a $119B serviceable available market, and a $2.97B near-term obtainable market based on targeted deployment for which there are already active conversations.

More than 2 billion people are living with or at high risk of metabolic and cardiovascular conditions, often without consistent access to early detection or preventive monitoring. As existing tools remain inefficient, expensive, and hard to scale, Viit Health offers a timely alternative: accessible, non-invasive, real-time monitoring designed for everyday use and population-level impact.

CROP marks Viit Health’s commercial activation.

This November, we will launch a paid, multi-center Cardiometabolic Risk Observation Program (CROP) under the supervision of the Hospital General de México.

Together with InBody and Daily Human, we are preparing to deploy 180 Viit Gen-4 units across corporate wellness initiatives, monitor 20,000+ people over 18 months, and generate approximately $3M in revenue.

The program combines Viit’s fast, non-invasive biomarker monitoring with InBody’s body composition analysis and Daily Human’s AI-powered healthy habits coaching — creating a scalable model for prevention, early risk observation, and long-term behavior change.

CROP is designed to show how Viit can bring prevention into real-world settings — helping organizations monitor cardiometabolic risk earlier, more frequently, and at scale.

Leading health experts, scientists, and investors recognize the urgent need for better tools to detect and manage chronic disease risk. That’s why Viit Health has gained support from a growing network of partners — including top research institutions in Mexico and the U.S., global health investors, engineering firms, and entrepreneurship organizations. Together, we’re building one of the most promising breakthroughs in consumer health: a scalable, science-backed platform for prevention that’s ready for the real world.

Viit Health is led by a rare combination of scientific expertise, financial acumen, and mission-driven entrepreneurship. Our team brings decades of experience across biotech, engineering, clinical research, and venture building — paired with a deep commitment to advancing public health through innovation. We’ve built and scaled startups, secured global partnerships, led cutting-edge research, and executed in both corporate and clinical environments. With a clear vision and a strong operational foundation, we’re committed to delivering measurable value for both our users and investors — while creating lasting impact in the fight against chronic disease.

Following our initial CROP deployment and first commercial revenue, Viit Health plans to raise a $3M Series A to accelerate the next phase of growth.

This round is expected to support regulatory execution, manufacturing scale-up, and preparation for broader commercial expansion. In January 2027, we will begin submissions with both the FDA and COFEPRIS as a Clinical Decision Support System (CDSS) for cardiometabolic risk observation, with approvals targeted by the end of 2027.

As we move through the regulatory process, we also plan to expand CROP by 220 additional units by July 2027, strengthening our real-world dataset and commercial traction.

By early 2028, Viit Health aims to begin broader expansion across the U.S. and Mexico, targeting pre-identified institutional channels for population-level monitoring. After 2028, we intend to expand across Latin America and add new biomarker capabilities such as oxidative stress, cholesterol, triglycerides, HbA1c, and other cardiometabolic markers.

The world faces a growing health and economic crisis: non-communicable diseases account for the vast majority of deaths, despite being largely preventable. What’s missing isn’t treatment — it’s access to early detection and practical prevention. Viit Health’s mission is to change that. After years of research, validation, and strategic partnerships, we’re ready to scale a breakthrough solution that delivers real-time, non-invasive health monitoring to individuals, healthcare providers, and public systems alike — with a model built for meaningful impact and strong, sustainable profitability.

This is a chance to be part of a global shift — toward smarter tools, healthier lives, and a more sustainable future.